---
title: "ALS渐冻症临床失败的秘密被最新蛋白组学技术解开！"
date: 2025-09-03T06:00:29Z
draft: ["false"]
tags: [
  "fetched",
  "循因缉药"
]
categories: ["Duty"]
---
ALS渐冻症临床失败的秘密被最新蛋白组学技术解开！ by 循因缉药
------
<div><section mpa-from-tpl="t" data-mpa-action-id="mf1wil9015cr" data-pm-slice="0 0 []"><span leaf="" mpa-font-style="mf1wkzuo24w9" data-mpa-action-id="mf1wkzv81dy0" data-pm-slice="0 0 []"><span textstyle="">我愿称之为：蛋白组学的魅力时刻</span></span></section><section data-mpa-template="t" mpa-data-temp-power-by="yiban.io" mpa-from-tpl="t" data-mpa-action-id="mf1wil90uzg"><section mpa-data-temp-power-by="yiban.io" mpa-from-tpl="t" data-mpa-action-id="mew6g72l2276" data-pm-slice="0 0 []"><section mpa-from-tpl="t"><section mpa-from-tpl="t"><section mpa-from-tpl="t"><section mpa-from-tpl="t"><p><span leaf="" mpa-is-content="t">2022年3月28日，渤健和合作伙伴Ionis Pharmaceuticals发布了肌萎缩侧索硬化症（ALS）的候选药物BIIB078临床试验结果：失败。</span></p><p><span leaf="" mpa-is-content="t">一线结果显示：该药物并没有显示出临床益处。</span></p><p><span leaf="" mpa-is-content="t">因此，渤健和Ionis因此决定终止其临床试验。</span></p><p><span leaf="" mpa-is-content="t">但是，究竟为什么药物无效导致临床失败？直到最近这个秘密才被揭开。</span></p></section></section></section></section></section></section><section data-mpa-template="t" mpa-data-temp-power-by="yiban.io" mpa-from-tpl="t" data-mpa-action-id="mf1wleyfzf3"><section data-mid="" mpa-from-tpl="t"><section data-mid="" mpa-from-tpl="t"><section data-mid="" mpa-from-tpl="t" nodeleaf=""><img data-src="https://mmbiz.qpic.cn/mmbiz_png/wbOfcvkM2SqC8YWOchic1cda37szmAeUGD1oJqm4OpTSWg6Wkycrp8BWZicg2vuOzRzwIenthJcY1ZQIvJRpNwnw/640" data-ratio="0.013793103448275862" data-w="580" src="https://mmbiz.qpic.cn/mmbiz_png/wbOfcvkM2SqC8YWOchic1cda37szmAeUGD1oJqm4OpTSWg6Wkycrp8BWZicg2vuOzRzwIenthJcY1ZQIvJRpNwnw/640"></section></section></section></section><p data-pm-slice="0 0 []"><span><span leaf=""><span textstyle="">2025年08月26日，美国埃默里大学联合梅奥诊所等研究团队在顶级期刊Cell上发表了题为《Molecular impact of antisense oligonucleotide therapy in C9orf72-associated ALS》的研究论文，深入剖析了反义寡核苷酸</span></span></span><span><span><span leaf=""><span textstyle="">（Antisense Oligonucleotide, ASO）药物BIIB078在C9orf72突变的肌萎缩侧索硬化症（c9ALS）患者中的分子作用机制。</span><span textstyle="">借助最新的</span></span></span></span><span data-pm-slice='1 1 ["para",{"tagName":"p","attributes":{"style":"-webkit-tap-highlight-color: transparent; margin: 0px 0px 8px; padding: 0px; outline: 0px; max-width: 100%; box-sizing: border-box !important; overflow-wrap: break-word !important; clear: both; min-height: 1em; color: rgba(0, 0, 0, 0.9); font-family: \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif; font-size: 17px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: 0.544px; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; visibility: visible;","data-pm-slice":"0 0 []"},"namespaceURI":"http://www.w3.org/1999/xhtml"}]'><span leaf=""><span textstyle="">NULISA</span></span></span><span><span leaf=""><span textstyle="">超灵敏蛋白组学技术，研究者筛选鉴定了CCL26作为BIIB078的新型药效学</span></span></span><span data-pm-slice='1 1 ["para",{"tagName":"p","attributes":{"style":"-webkit-tap-highlight-color: transparent;margin: 0px 0px 8px;padding: 0px;outline: 0px;max-width: 100%;clear: both;min-height: 1em;color: rgba(0, 0, 0, 0.9);font-family: \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;font-size: 17px;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: 0.544px;orphans: 2;text-align: justify;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;background-color: rgb(255, 255, 255);text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;visibility: visible;box-sizing: border-box !important;overflow-wrap: break-word !important;","data-pm-slice":"0 0 []"},"namespaceURI":"http://www.w3.org/1999/xhtml"}]'><span leaf=""><span textstyle="">（pharmacodynamic，PD）</span></span></span><span><span leaf=""><span textstyle="">生物标志物</span></span></span><span><span leaf=""><span textstyle="">，并强调ASO疗法亟需新的、可靠的生物标志物，这对未来ASO疗法设计和神经退行性疾病治疗具有重要指导作用，对其他复杂疾病的治疗也具有广泛的意义。</span></span></span></p><section nodeleaf="" data-mpa-action-id="mf1vjr3n1v1u" data-pm-slice="0 0 []"><img data-src="https://mmbiz.qpic.cn/mmbiz_png/TlfYVOrDyb6YhfYWCYiap9eicHTibRiaTzkqW2zKEUPZHvNp0hmouRaccibeuyAD1JrTQ04mGVNvWicpw16K6mIm8huA/640?wx_fmt=png&amp;from=appmsg#imgIndex=0" data-ratio="0.7564814814814815" data-s="300,640" data-type="png" data-w="1080" type="block" data-imgfileid="100000653" src="https://mmbiz.qpic.cn/mmbiz_png/TlfYVOrDyb6YhfYWCYiap9eicHTibRiaTzkqW2zKEUPZHvNp0hmouRaccibeuyAD1JrTQ04mGVNvWicpw16K6mIm8huA/640?wx_fmt=png&amp;from=appmsg#imgIndex=0"></section><p data-pm-slice="0 0 []"><b><span><span leaf=""><span textstyle="">研究背景</span></span></span></b></p><section><span><span leaf=""><span textstyle="">肌萎缩侧索硬化症</span></span></span><span><span><span leaf=""><span textstyle="">（</span></span></span><span><span leaf=""><span textstyle="">Amyotrophic Lateral Sclerosis，</span></span></span></span><span><span leaf=""><span textstyle="">ALS</span></span></span><span><span><span leaf=""><span textstyle="">，渐冻</span></span></span><span><span leaf=""><span textstyle="">症</span></span></span></span><span><span leaf=""><span textstyle="">）是一种致</span></span></span><span><span leaf=""><span textstyle="">命的进行性神经退行性疾病，其特征是运动皮层和脊髓运动神经元缺失。在所有</span></span></span><span><span leaf=""><span textstyle="">ALS</span></span></span><span><span leaf=""><span textstyle="">病例中，</span></span></span><i><span><span leaf=""><span textstyle="">C9orf72</span></span></span></i><span><span leaf=""><span textstyle="">基因的第一个内含子中</span></span></span><span><span leaf=""><span textstyle="">G</span></span></span><sub><span><span leaf=""><span textstyle="">4</span></span></span></sub><span><span leaf=""><span textstyle="">C</span></span></span><sub><span><span leaf=""><span textstyle="">2</span></span></span></sub><span><span leaf=""><span textstyle="">重复序列的异常扩增是最常见的遗传原因，这种扩增导致了毒性</span></span></span><span><span leaf=""><span textstyle="">RNA</span></span></span><span><span leaf=""><span textstyle="">转录本和双肽重复蛋白（</span></span></span><span><span leaf=""><span textstyle="">DPR</span></span></span><span><span leaf=""><span textstyle="">）的产生，从而引发神经元损伤。</span></span></span></section><section><span><span leaf=""><span textstyle="">针对这一明确病因，</span></span></span><span><span leaf=""><span textstyle="">Biogen</span></span></span><span><span leaf=""><span textstyle="">和</span></span></span><span><span leaf=""><span textstyle="">Ionis</span></span></span><span><span leaf=""><span textstyle="">公司联合开发了基于</span></span></span><span leaf=""><span textstyle="">反义寡核苷酸</span></span><span><span><span leaf=""><span textstyle="">（ASO）</span></span></span><span><span leaf=""><span textstyle="">疗法的药物</span></span></span></span><span><span leaf=""><span textstyle="">BII</span></span></span><span><span leaf=""><span textstyle="">B078</span></span></span><span><span><span leaf=""><span textstyle="">（</span></span></span><span><span leaf=""><span textstyle="">通用名tadunersen）</span></span></span></span><span><span leaf=""><span textstyle="">，这是一款靶向</span></span></span><i><span><span leaf=""><span textstyle="">C9orf72</span></span></span></i><span><span leaf=""><span textstyle="">的</span></span></span><span><span leaf=""><span textstyle="">G</span></span></span><sub><span><span leaf=""><span textstyle="">4</span></span></span></sub><span><span leaf=""><span textstyle="">C</span></span></span><sub><span><span leaf=""><span textstyle="">2</span></span></span></sub><span><span leaf=""><span textstyle="">重复转录本的混合骨架“</span></span></span><span><span leaf=""><span textstyle="">gapmer</span></span></span><span><span leaf=""><span textstyle="">”型</span></span></span><span><span leaf=""><span textstyle="">ASO</span></span></span><span><span leaf=""><span textstyle="">，通过</span></span></span><span><span leaf=""><span textstyle="">RNAase-H</span></span></span><span><span leaf=""><span textstyle="">介导的剪切来降解毒性</span></span></span><span><span leaf=""><span textstyle="">G</span></span></span><sub><span><span leaf=""><span textstyle="">4</span></span></span></sub><span><span leaf=""><span textstyle="">C</span></span></span><sub><span><span leaf=""><span textstyle="">2</span></span></span></sub><span><span leaf=""><span textstyle="">重复转录本。</span><span textstyle="">尽管在临床前研究中，</span></span></span><span><span leaf=""><span textstyle="">BIIB078</span></span></span><span><span leaf=""><span textstyle="">能够沉默</span></span></span><span><span leaf=""><span textstyle="">G</span></span></span><sub><span><span leaf=""><span textstyle="">4</span></span></span></sub><span><span leaf=""><span textstyle="">C</span></span></span><sub><span><span leaf=""><span textstyle="">2</span></span></span></sub><span><span leaf=""><span textstyle="">重复转录的表达和</span></span></span><span><span leaf=""><span textstyle="">DPR</span></span></span><span><span leaf=""><span textstyle="">的减</span></span></span><span><span><span leaf=""><span textstyle="">少，但是临床试验因未能带来临床获益而终止。</span></span></span></span></section><p><span><span leaf=""><span textstyle="">本研究旨在通过对接受</span></span></span><span><span leaf=""><span textstyle="">BIIB078</span></span></span><span><span leaf=""><span textstyle="">治疗的</span></span></span><span><span leaf=""><span textstyle="">c9ALS</span></span></span><span><span leaf=""><span textstyle="">患者进行多维度的分子和神经病理分析，明确</span></span></span><span><span leaf=""><span textstyle="">BIIB078</span></span></span><span><span leaf=""><span textstyle="">在中枢神经的分布特征、对疾病病理的影响、体内免疫应答及更优的药效标志物，为未来</span></span></span><span><span leaf=""><span textstyle="">ASO</span></span></span><span><span leaf=""><span textstyle="">疗法的优化提供重要依据。</span></span></span><p></p></p><p><b><span><span leaf=""><span textstyle="">关键研究方法和结果</span></span></span><span><p></p></span></b></p><ul><li><b><span><span leaf=""><span textstyle="">ASO</span></span></span></b><b><span><span leaf=""><span textstyle="">治疗后</span></span></span><span><span leaf=""><span textstyle="">c9ALS</span></span></span></b><b><span><span leaf=""><span textstyle="">患者体液生物标志物分析</span></span></span></b><span><span leaf=""><span textstyle="">：</span></span></span><span><span leaf=""><span textstyle="">免疫测定ASO</span></span></span><span><span leaf=""><span textstyle="">治疗后的</span></span></span><span><span leaf=""><span textstyle="">c9ALS</span></span></span><span><span leaf=""><span textstyle="">患者脑脊液中</span></span></span><span><span leaf=""><span textstyle="">poly(GP)</span></span></span><span><span leaf=""><span textstyle="">（</span></span></span><span><span leaf=""><span textstyle="">DPR</span></span></span><span><span leaf=""><span textstyle="">标志物）和</span></span></span><span><span leaf=""><span textstyle="">BIIB078</span></span></span><span><span leaf=""><span textstyle="">的含量，发现</span></span></span><span><span leaf=""><span textstyle="">6</span></span></span><span><span leaf=""><span textstyle="">例患者中有</span></span></span><span><span leaf=""><span textstyle="">5</span></span></span><span><span leaf=""><span textstyle="">例患者的</span></span></span><span><span leaf=""><span textstyle="">poly(GP)</span></span></span><span><span leaf=""><span textstyle="">降低（平均降低</span></span></span><span><span leaf=""><span textstyle="">37.2%</span></span></span><span><span leaf=""><span textstyle="">），但个体差异显著，且临床评分没有相关性（</span></span></span><span><span leaf=""><span textstyle="">ALSFRS-R</span></span></span><span><span leaf=""><span textstyle="">）。</span></span></span><span><span leaf=""><span textstyle="">BIIB078</span></span></span><span><span leaf=""><span textstyle="">的含量和</span></span></span><span><span leaf=""><span textstyle="">poly(GP)</span></span></span><span><span leaf=""><span textstyle="">的水平也呈现很大的个体差异，</span></span></span><span><span leaf=""><span textstyle="">4</span></span></span><span><span leaf=""><span textstyle="">例患者没有相关性，</span></span></span><span><span leaf=""><span textstyle="">2</span></span></span><span><span leaf=""><span textstyle="">例存在相关性，这说明</span></span></span><span><span leaf=""><span textstyle="">poly(GP)</span></span></span><span><span leaf=""><span textstyle="">并不是可靠的</span></span></span><span><span leaf=""><span textstyle="">BIIB078</span></span></span><span><span leaf=""><span textstyle="">药效评估指标。</span></span></span><p></p><b><span leaf=""><br></span></b></li></ul><section nodeleaf=""><img data-src="https://mmbiz.qpic.cn/mmbiz_png/TlfYVOrDyb6YhfYWCYiap9eicHTibRiaTzkq3Aaic0icmicvWPjUcDluYngVkHV5tBqrDBBHddibyJ78aNhvSbF2odoDuw/640?wx_fmt=png&amp;from=appmsg#imgIndex=1" data-ratio="0.3574074074074074" data-s="300,640" data-type="png" data-w="1080" type="block" data-imgfileid="100000657" src="https://mmbiz.qpic.cn/mmbiz_png/TlfYVOrDyb6YhfYWCYiap9eicHTibRiaTzkq3Aaic0icmicvWPjUcDluYngVkHV5tBqrDBBHddibyJ78aNhvSbF2odoDuw/640?wx_fmt=png&amp;from=appmsg#imgIndex=1"></section><ul><li><b><span><span leaf=""><span textstyle="">BIIB078</span></span></span></b><b><span><span leaf=""><span textstyle="">治疗后</span></span></span><span><span leaf=""><span textstyle="">c9ALS</span></span></span></b><b><span><span leaf=""><span textstyle="">患者免疫图谱分析和新型药效学生物标志物筛选</span></span></span></b><span><span leaf=""><span textstyle="">：</span><span textstyle="">为了筛选鉴定BIIB078</span></span></span><span><span leaf=""><span textstyle="">药效评估的可靠标志物，研究人员采用了</span></span></span><b><span><span leaf=""><span textstyle="">NULISA</span></span></span></b><span><span leaf=""><span textstyle="">（</span></span></span><span><span leaf=""><span textstyle="">NUcleic acid Linked Immuno-Sandwich Assay</span></span></span><span><span leaf=""><span textstyle="">）超灵</span></span></span><span><span leaf=""><span textstyle="">敏蛋白组学技术</span></span></span><span><span leaf=""><span textstyle="">（该技术检测灵敏度可达fg/mL级别，同时可在uL级的临床样本中一次性系统性定量检测数百种蛋白靶标</span></span></span><span><span leaf=""><span textstyle="">）</span></span></span><span><span leaf=""><span textstyle="">，借助</span></span></span><b><span><span leaf=""><span textstyle="">NULISAseq中枢神经系统检测试剂盒（120+靶标）和</span></span></span><span><span leaf=""><span textstyle="">NULISAseq炎症和免疫检测试剂盒（250靶标)【具体检测靶标清单见文末】</span><span textstyle="">，分析了6例接受BIIB078治疗的c9ALS患者的79个脑脊液</span></span></span><span><span leaf=""><span textstyle="">（</span></span></span><span><span leaf=""><span textstyle="">Cerebrospinal Fluid, </span></span></span><span><span leaf=""><span textstyle="">CSF）样</span></span></span><span><span leaf=""><span textstyle="">本，比较第一次和最后一次给药后的蛋白水平。结果发现，促炎细胞因子和细胞因子受体显著增加，包括TNFRSF11B、CSFR2B、GDF15和CCL26等。其中CCL26在所有病例和时间点表现出稳健且持续的增加，而且CCL26在两个NULISAseq Panel中呈现非常一致的结果。</span><span textstyle="">经过独立免疫测定也验证了CCL26可作为BIIB078</span></span></span></b><span><span leaf=""><span textstyle="">的药效学生物标志物。</span></span></span><section nodeleaf=""><img data-src="https://mmbiz.qpic.cn/mmbiz_png/TlfYVOrDyb6YhfYWCYiap9eicHTibRiaTzkqfgolxsZKg3nLxx3kiaS7soT2pLxUTtahufzOcEUL8icqp14HhmfPM4xQ/640?wx_fmt=png&amp;from=appmsg#imgIndex=2" data-ratio="0.5287037037037037" data-s="300,640" data-type="png" data-w="1080" type="block" data-imgfileid="100000656" src="https://mmbiz.qpic.cn/mmbiz_png/TlfYVOrDyb6YhfYWCYiap9eicHTibRiaTzkqfgolxsZKg3nLxx3kiaS7soT2pLxUTtahufzOcEUL8icqp14HhmfPM4xQ/640?wx_fmt=png&amp;from=appmsg#imgIndex=2"></section></li><li><b><span><span leaf=""><span textstyle="">BIIB078</span></span></span></b><b><span><span leaf=""><span textstyle="">药物在中枢神经的分布</span></span></span></b><span><span leaf=""><span textstyle="">：</span><span textstyle="">通过免疫组化、</span><span textstyle="">原位杂交（RNAscope)</span><span textstyle="">及板式寡核苷酸电化学发光免疫测定(POE)</span></span></span><span><span leaf=""><span textstyle="">分析，发现</span></span></span><span><span leaf=""><span textstyle="">BIIB078</span></span></span><span><span leaf=""><span textstyle="">在中枢神经系统广泛分布。且给药剂量越高，组织中</span></span></span><span><span leaf=""><span textstyle="">BIIB078</span></span></span><span><span leaf=""><span textstyle="">浓度越高，脊髓中含量也与其它脑区浓度呈正相关性。证明了鞘内注射的</span></span></span><span><span leaf=""><span textstyle="">BIIB078</span></span></span><span><span leaf=""><span textstyle="">可广泛渗透中枢神经系统，分布特征也与给药时间和剂量相关。</span></span></span><p></p></li><li><b><span><span leaf=""><span textstyle="">BIIB078</span></span></span></b><b><span><span leaf=""><span textstyle="">治疗患者的</span></span></span><span><span leaf=""><span textstyle="">c9orf72</span></span></span></b><b><span><span leaf=""><span textstyle="">及相关病理标志物分析</span></span></span></b><span><span leaf=""><span textstyle="">：</span><span textstyle="">定量PCR</span></span></span><span><span leaf=""><span textstyle="">分析发现</span></span></span><span><span leaf=""><span textstyle="">C9orf72</span></span></span><span><span leaf=""><span textstyle="">总转录水平在</span></span></span><span><span leaf=""><span textstyle="">BIIB078</span></span></span><span><span leaf=""><span textstyle="">治疗组和对照组中没有差异，内含子</span></span></span><span><span leaf=""><span textstyle="">G</span></span></span><sub><span><span leaf=""><span textstyle="">4</span></span></span></sub><span><span leaf=""><span textstyle="">C</span></span></span><sub><span><span leaf=""><span textstyle="">2</span></span></span></sub><span><span leaf=""><span textstyle="">转录本虽然呈降低趋势但无统计学差异。用串联质谱（</span></span></span><span><span leaf=""><span textstyle="">TMT-MS</span></span></span><span><span leaf=""><span textstyle="">）检测</span></span></span><span><span leaf=""><span textstyle="">C9orf72</span></span></span><span><span leaf=""><span textstyle="">蛋白在脊髓中的丰度，</span></span></span><span><span leaf=""><span textstyle="">ASO</span></span></span><span><span leaf=""><span textstyle="">治疗前后也无统计变化。而且标志物</span></span></span><span><span leaf=""><span textstyle="">poly(GP)</span></span></span><span><span leaf=""><span textstyle="">、</span></span></span><span><span leaf=""><span textstyle="">poly(GA)</span></span></span><span><span leaf=""><span textstyle="">、</span></span></span><span><span leaf=""><span textstyle="">pTDP-43</span></span></span><span><span leaf=""><span textstyle="">以及</span></span></span><span><span leaf=""><span textstyle="">tSTMN2</span></span></span><span><span leaf=""><span textstyle="">的水平，在治疗组和对照组无差异，这表明</span></span></span><span><span leaf=""><span textstyle="">BIIB078</span></span></span><span><span leaf=""><span textstyle="">未能有效清除中枢神经系统中</span></span></span><span><span leaf=""><span textstyle="">c9orf72</span></span></span><span><span leaf=""><span textstyle="">毒性蛋白及相关病理指标。</span></span></span><section><span leaf=""><br></span></section></li></ul><p data-pm-slice="0 0 []"><b><span><span leaf=""><span textstyle="">研究意义和展望</span></span></span></b></p><p><span leaf=""><span textstyle="">2022 年 3 月，Biogen 和 Ionis 公司因 ASO 药物 BIIB078 未能改善渐冻症患者临床获益，宣布终止联合开发。</span></span><span leaf=""><span textstyle="">BIIB078 虽能在部分患者中降低脑脊液 poly (GP)，但无法有效清除中枢神经系统内的 c9orf72 毒性蛋白（如 DPR、pTDP-43），且药物分布与病理改善无显著关联。</span></span><span leaf=""><br></span></p><p><span leaf=""><span textstyle="">本研究通过多维度整合分析 BIIB078 治疗患者数据，在分子层面深入解析了其临床试验失败的深层机制，为渐冻症乃至神经退行性疾病治疗领域提供了宝贵的经验教训。</span></span><p></p></p><p><span leaf=""><span textstyle="">本研究清晰地揭示了既往药效学标志物（如 poly(GP)）与大脑组织中的核心病理改变之间可能存在的巨大脱节。这表明，药物临床试验亟需更为准确、可靠、稳定的药效评估标志物。而筛选鉴定更可靠的新型标志物，需要兼具突破性灵敏度和超多重能力的蛋白组学技术。本研究正是采用了 </span><span textstyle="">NULISA 技</span></span><span><span leaf=""><span textstyle="">术</span><span textstyle="">，</span></span></span><span data-pm-slice="0 0 []"><span leaf=""><span textstyle="">借助其个位数 </span><span textstyle="">fg/mL 级</span><span textstyle="">的检测灵敏度</span></span></span><span><span leaf=""><span textstyle="">、可以从</span><span textstyle="">uL级的临床样本</span><span textstyle="">中系统性定量检测</span><span textstyle="">数百种蛋白</span><span textstyle="">靶标的性能，首次在人类中枢神经系统中，系统地描绘了 A</span></span></span><span leaf=""><span textstyle="">SO 药物可以引发的持续的、可被监测的免疫应答，并成功筛选得到了 BIIB078 的药效学生物标志物 CCL26。</span></span><span leaf=""><br></span></p><p><span leaf=""><span textstyle="">NULISA 技术自 2024 年 1 月商业化以来，已经得到了逾百家研究机构和制药企业的采用，包括哈佛大学、斯坦福大学、香港科技大学、首都医学科学创新中心、赛诺菲、礼来、昱言科技、镁景科技等。我们期待NULISA技术持续在全球范围内，助力加速复杂疾病（神经退行性疾病、自身免疫性疾病等）的药物研发和临床转化进程。</span></span></p><p><span leaf=""><span textstyle="">本研究采用了 NULISA 和 RNAscope 两项技术--这两项技术均由罗宇龄博士领衔的团队分别在 Alamar 和 ACD 公司发明和商业化。</span></span></p><p data-pm-slice="0 0 []"><strong><span leaf="">参考文献</span></strong></p><p><span leaf="">[1]. </span><span leaf="">Zachary T. McEachin, Mingee Chung et al. </span><b><span leaf="">Molecular impact of antisense oligonucleotide therapy in </span><i><span leaf="">C9orf72</span></i><span leaf="">-associated </span></b><b><span leaf="">ALS</span></b><span leaf="">. </span><span><span leaf=""><span textstyle="">Cell</span> <span textstyle="">188</span>, 1–12, November 13, 2025</span></span></p><p data-pm-slice="0 0 []"><strong><span data-pm-slice='1 1 ["para",{"tagName":"p","attributes":{"data-pm-slice":"0 0 []","style":"-webkit-tap-highlight-color: transparent; margin: 0px 0px 8px; padding: 0px; outline: 0px; max-width: 100%; box-sizing: border-box !important; overflow-wrap: break-word !important; clear: both; min-height: 1em; color: rgba(0, 0, 0, 0.9); font-family: \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif; font-size: 17px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; background-color: rgb(255, 255, 255); letter-spacing: 0.578px; line-height: 1em; visibility: visible;"},"namespaceURI":"http://www.w3.org/1999/xhtml"},"node",{"tagName":"strong","attributes":{"style":"-webkit-tap-highlight-color: transparent; margin: 0px; padding: 0px; outline: 0px; max-width: 100%; box-sizing: border-box !important; overflow-wrap: break-word !important;"},"namespaceURI":"http://www.w3.org/1999/xhtml"}]'><span leaf=""><span textstyle="">本研究采用的NULISA检测Panel靶标清单</span></span></span></strong></p><section nodeleaf="" data-mpa-action-id="mf1vmk49uya" data-pm-slice="0 0 []"><img data-src="https://mmbiz.qpic.cn/mmbiz_png/TlfYVOrDyb5zxDdrUdGBq7iaJU2auKhlY7QsWrk9ejuQ5ibofEXeqAa4EMQ9pzX0dEiaRiav2BsLibicw1TicCfAa9nzQ/640?wx_fmt=png&amp;from=appmsg#imgIndex=3" data-ratio="0.5092592592592593" data-s="300,640" data-w="1080" type="block" data-imgfileid="100000626" src="https://mmbiz.qpic.cn/mmbiz_png/TlfYVOrDyb5zxDdrUdGBq7iaJU2auKhlY7QsWrk9ejuQ5ibofEXeqAa4EMQ9pzX0dEiaRiav2BsLibicw1TicCfAa9nzQ/640?wx_fmt=png&amp;from=appmsg#imgIndex=3"></section><section nodeleaf="" data-mpa-action-id="mf1vmo2f3vk" data-pm-slice="0 0 []"><img data-src="https://mmbiz.qpic.cn/mmbiz_png/TlfYVOrDyb5zxDdrUdGBq7iaJU2auKhlYP6X8Jv13h0qDgNaZEbDjPJJHczrvPh0SjnNRbcNVfyibaoYnro7gxEw/640?wx_fmt=png&amp;from=appmsg#imgIndex=4" data-ratio="0.5370370370370371" data-s="300,640" data-w="1080" type="block" data-imgfileid="100000625" src="https://mmbiz.qpic.cn/mmbiz_png/TlfYVOrDyb5zxDdrUdGBq7iaJU2auKhlYP6X8Jv13h0qDgNaZEbDjPJJHczrvPh0SjnNRbcNVfyibaoYnro7gxEw/640?wx_fmt=png&amp;from=appmsg#imgIndex=4"></section><section mpa-from-tpl="t" data-mpa-action-id="mf1vol3e149j" data-pm-slice="0 0 []"><span leaf=""><br></span></section><section data-mpa-template="t" mpa-data-temp-power-by="yiban.io" mpa-from-tpl="t" data-mpa-action-id="mf1vol3ertn"><section data-mid="" mpa-from-tpl="t"><section data-mid="" mpa-from-tpl="t"><section data-mid="" mpa-from-tpl="t"><section data-mid="" mpa-from-tpl="t" nodeleaf=""><img data-src="https://mmbiz.qpic.cn/mmbiz_png/632JHKFGz4rRa4jwy8a6zPbSIB21nLXuHnMhpEwq0sHR3acL7oa4dwxCQCfDk8KVYvfokPVOswLc4OOSq9AtpQ/640?from=appmsg&amp;wx_fmt=png" data-ratio="0.8823529411764706" data-w="34" data-imgfileid="100026825" src="https://mmbiz.qpic.cn/mmbiz_png/632JHKFGz4rRa4jwy8a6zPbSIB21nLXuHnMhpEwq0sHR3acL7oa4dwxCQCfDk8KVYvfokPVOswLc4OOSq9AtpQ/640?from=appmsg&amp;wx_fmt=png"></section><section data-mid="" mpa-from-tpl="t"><section data-mid="" mpa-from-tpl="t"><p data-mid="" yb-mpa-mark="mark-main-title"><span leaf="">公司介绍</span><span leaf=""><br></span></p></section><section data-mid="" mpa-from-tpl="t" nodeleaf=""><img data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/p4AJQW54D7cVcotID0L89pdf5QafqkzdBtok9Yk61u7koibVpbARugClaSKsDEp6t4OxWJpeLbgeLv2zukQ1T4g/640?from=appmsg&amp;wx_fmt=png" data-ratio="0.8409090909090909" data-w="88" data-imgfileid="100026824" src="https://mmbiz.qpic.cn/sz_mmbiz_png/p4AJQW54D7cVcotID0L89pdf5QafqkzdBtok9Yk61u7koibVpbARugClaSKsDEp6t4OxWJpeLbgeLv2zukQ1T4g/640?from=appmsg&amp;wx_fmt=png"></section></section><section data-mid="" mpa-from-tpl="t"><p data-mid=""><span leaf="">COMPANY INTRODUCTION</span><span leaf=""><br></span></p></section></section></section></section></section><section data-pm-slice="5 3 []"><span><strong><span><span><span leaf=""><br></span></span></span></strong></span></section><section data-pm-slice="5 3 []"><span><strong><span><span><span leaf=""><span textstyle="">关于爱拉码生物（Alamar Biosciences）</span></span></span></span><span leaf=""><br></span></strong></span></section><section><span data-pm-slice="0 0 []"><span leaf="">爱拉码生物由知名科学家、发明家罗宇龄博士（</span><span><span><span leaf="">RNAscope</span><span><span leaf="">™</span></span><span leaf="">技术主发明人，NULISA™技术主发明人</span></span></span><span leaf="">）带领团队于2018年创立，是一家创新的飞克级全自动蛋白组学平台公司，其使命是通过精准蛋白质组学实现疾病的早期检测。</span></span></section><p><span><span leaf="">公司专利的NULISA</span><span><span leaf="">™</span></span><span leaf="">技术和ARGO™ HT自动化平台相结合，作为兼具“超灵敏”和“超多重”检测性能的突破性蛋白检测系统，在同一个平台上同时具备 “高通量蛋白质组学” 和 “聚焦蛋白标志物” 两种检测模式。借助fg/mL级的灵敏度，超多重检测能力，12个log的动态范围，全自动工作流程和一以贯之的特异性，形成了第一个有机会赋能蛋白标志物 “从发现、验证、到转化” 完整生命周期的技术平台。</span></span></p><section><span><strong><span><span><span leaf=""><span textstyle="">联系我们</span></span></span></span></strong></span><p></p></section><section><span><span leaf="">如果您希望进一步了解Alamar Biosciences的相关产品和技术，请在公众号留言，或发送电邮至：info@alamarbio.com，或请</span><span><span leaf="">访问https://alamarbio.com</span></span><span leaf="">。</span></span><span><span leaf="">我们期待和您一起，聚焦临床需求，深挖科学问题，共同推进疾病早筛早诊和分期分型，加速精准医学的转化进程。</span></span></section><section nodeleaf=""><mp-common-profile data-pluginname="mpprofile" data-nickname="Alamar Biosciences" data-alias="Alamar_Biosciences" data-from="0" data-headimg="http://mmbiz.qpic.cn/mmbiz_png/TlfYVOrDyb7vAxWdJKqUwaE4IG3TiaulQfQGwgRJpDyVSCBARV8ameiaZ2oLNbc9fECbU863SjicmR8qCvbmAGh3A/0?wx_fmt=png" data-signature="NULISA技术：超灵敏（0.2fg/mL），超多重（数百重），超宽动态范围（12个log），全自动（ARGO HT设备平台），采用一以贯之的单克隆抗体对… 真正陪伴蛋白标志物从发现到转化全生命周期！【面向转化的精准蛋白检测平台】" data-id="MzIzNTQ0ODY1OA==" data-is_biz_ban="0" data-service_type="1" data-verify_status="0"></mp-common-profile></section><section><span><section><span><span leaf="">↑↑↑</span><span leaf="" data-pm-slice='1 1 ["para",{"tagName":"section","attributes":{"style":"margin: 8px 0px;padding: 0px;outline: 0px;max-width: 100%;color: rgba(0, 0, 0, 0.9);font-size: 17px;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: 0.544px;orphans: 2;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;font-family: system-ui, -apple-system, \"system-ui\", \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(255, 255, 255);text-align: left;line-height: 1em;box-sizing: border-box !important;overflow-wrap: break-word !important;"},"namespaceURI":"http://www.w3.org/1999/xhtml"},"node",{"tagName":"span","attributes":{"style":"margin: 0px;padding: 0px;outline: 0px;max-width: 100%;color: rgb(136, 136, 136);font-size: 13px;box-sizing: border-box !important;overflow-wrap: break-word !important;"},"namespaceURI":"http://www.w3.org/1999/xhtml"}]'>欢迎关注，了解更多技术信息和资讯↑↑↑</span></span></section></span></section><section><span><span leaf=""><img data-src="https://mmbiz.qpic.cn/mmbiz_png/TlfYVOrDyb6AzNlZsAmM1S5Ckv6FIEicL3icrcpCBJdCeuuAUnhlwgic48JwMO6SAWjcbyq36RMZia6d4aDP5yxhQw/640?wx_fmt=png#imgIndex=5" data-ratio="0.15599343185550082" data-s="300,640" data-type="other" data-w="609" data-imgfileid="100000253" src="https://mmbiz.qpic.cn/mmbiz_png/TlfYVOrDyb6AzNlZsAmM1S5Ckv6FIEicL3icrcpCBJdCeuuAUnhlwgic48JwMO6SAWjcbyq36RMZia6d4aDP5yxhQw/640?wx_fmt=png#imgIndex=5"></span></span></section><p><mp-style-type data-value="3"></mp-style-type></p></div>  
<hr>
<a href="https://mp.weixin.qq.com/s/CiG8m9dYAdc_-XTidhDDRg",target="_blank" rel="noopener noreferrer">原文链接</a>
